SEC Form SC 13G/A filed by Lantheus Holdings Inc. (Amendment)
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/18/2024 | $143.00 | Buy | Goldman |
9/3/2024 | $175.00 | Buy | Redburn Atlantic |
7/10/2024 | $100.00 → $130.00 | Mkt Outperform | JMP Securities |
12/18/2023 | Outperform → Mkt Perform | William Blair | |
12/4/2023 | $100.00 | Outperform | TD Cowen |
9/29/2023 | Outperform | William Blair | |
3/8/2023 | $120.00 | Mkt Outperform | JMP Securities |
11/30/2022 | Outperform | SVB Leerink |